ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

LEO Pharma and Huadong Medicine side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

LEO PharmaHuadong Medicine
studies on the registry25462
open to participants now546
phase 3 studies under way312
reach primary completion within a year316
programswith a study of their own in two years117

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseLEO PharmaHuadong Medicine
Phase 100%

Huadong Medicine: 7 of its 17 programs at phase 1

  1. HDM2005phase 1
  2. HDM2020phase 1
  3. HDM2006phase 1
  4. HDM2012phase 1
  5. HDM2024phase 1

and 2 more — sign in to see them all

41%
Phase 200%

Huadong Medicine: 1 of its 17 programs at phase 2

  1. HDM2017phase 2
6%
Phase 3

LEO Pharma: 1 of its 1 programs at phase 3

  1. delgocitinibphase 3
100%

Huadong Medicine: 8 of its 17 programs at phase 3

  1. HDM1002phase 3
  2. HDM1005phase 3
  3. DR10624phase 3
  4. Roflumilastphase 3
  5. HDM1702phase 3

and 3 more — sign in to see them all

47%
Approved, new studies00%

Huadong Medicine: 1 of its 17 programs at approved, new studies

  1. janagliflozinapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
LEO Pharma1 readouts · 0 phase 3·······

LEO Pharma, Jun ’27: 1 program whose next study reaches primary completion

  1. delgocitinibphase 3 · Jun 4 · NCT07013201
····
Huadong Medicine9 readouts · 2 phase 3·

Huadong Medicine, Dec ’26: 2 programs whose next study reaches primary completion

  1. HDM1005phase 3 · Dec 1 · NCT07502001
  2. HDM2017phase 2 · Dec 31 · NCT07274085

Huadong Medicine, Jan ’27: 1 program whose next study reaches primary completion

  1. HDM2020phase 1 · Jan 31 · NCT07638891

Huadong Medicine, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. HDM1002phase 3 · Feb 16 · NCT07082114
·

Huadong Medicine, Apr ’27: 1 program whose next study reaches primary completion

  1. HDM2024phase 1 · Apr 15 · NCT07539285
·

Huadong Medicine, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Roflumilastphase 3 · Jun 30 · NCT07683806

Huadong Medicine, Jul ’27: 1 program whose next study reaches primary completion

  1. HDM2005phase 1 · Jul 1 · NCT07004296

Huadong Medicine, Aug ’27: 1 program whose next study reaches primary completion

  1. Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Lenphase 1 · Aug 10 · NCT07697339
·

Huadong Medicine, Oct ’27: 1 program whose next study reaches primary completion

  1. HDM2012phase 1 · Oct 0 · NCT07100249
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

LEO Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Huadong Medicine

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionLEO PharmaHuadong Medicine
Psoriasisboth · compare here

LEO Pharma in Psoriasis: 1 program

  1. delgocitinibphase 3

Their studies: LEO Pharma’s studies of Psoriasis in search

Huadong Medicine in Psoriasis: 3 programs

  1. Roflumilastphase 3
  2. betamethasone dipropionatephase 3
  3. calcipotrienephase 3

Their studies: Huadong Medicine’s studies of Psoriasis in search

Dermatitis, Atopicboth · compare here

LEO Pharma in Dermatitis, Atopic: 1 program

  1. delgocitinibphase 3

Their studies: LEO Pharma’s studies of Dermatitis, Atopic in search

Huadong Medicine in Dermatitis, Atopic: 2 programs

  1. Roflumilastphase 3
  2. betamethasone dipropionatephase 3

Their studies: Huadong Medicine’s studies of Dermatitis, Atopic in search

Alopecia Areataboth · compare here

LEO Pharma in Alopecia Areata: 1 program

  1. delgocitinibphase 3

Their studies: LEO Pharma’s studies of Alopecia Areata in search

Huadong Medicine in Alopecia Areata: 1 program

  1. calcipotrienephase 3

Their studies: Huadong Medicine’s studies of Alopecia Areata in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: LEO Pharma 1 of 1 · Huadong Medicine 5 of 17 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.